touchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease.
The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer’s Disease’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.
Questions:
- Why is lenalidomide considered a potentially promising drug in the treatment of mild cognitive impairment in Alzheimer’s disease? (0:15)
- What is already known about the benefits of lenalidomide and thalidomide in AD? (2:23)
- What are the aims and design of the MCLENA study? (3:05)
- What are the clinical endpoints in the MCLENA study? (4:35)
- What data has been accrued to date? (5:07)
- What future developments do you have planned? (5:35)
Disclosures: Marwan Sabbagh has ownership interest (stock or stock options) in Brain Health Inc, NeuroReserve, NeuroTau, Optimal Cognitive Health Company, uMethod Health, Versanum, Athira; has been a consultant for Alzheon, Neurotrope, Biogen, Cortexyme, Danone, Regeneron, Roche-Genentech, Stage 2 Innovations, Acadia; and has royalties with HarperCollins. Marwan Sabbagh is also part of the speakers bureau for Health and Wellness Partners and Joyce Knapp Communications.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AD/PD Virtual 2021.
